“...pleasure and pain, they come and go and don't last... bear them patiently”
—Gita
Pathos InvestmentsEquity Research
Research  ›  Fact Sheets  ›  ABBV

ABBVIE INC.

LISTEDNYSE
SYMBOLABBV
SIC2834
STATE OF INC.DE
FISCAL YEAR ENDSDecember 31
CIK1551152

PHARMACEUTICAL PREPARATIONS · LARGE ACCELERATED FILER · 10 FISCAL YEARS OF SEC XBRL DATA, 2016–2025

REVENUES, NET INCOME AND FREE CASH FLOW BY FISCAL YEAR$ billions0204060802016201720182019202020212022202320242025RevenuesNet incomeFree cash flowEARNINGS AND DIVIDENDS PER SHARE$ per share0.002.004.006.008.002016201720182019202020212022202320242025EPS dilutedDividends per share

Fiscal years labelled by the calendar year in which they end. Bars in $ billions; per-share figures as reported.

CAPITALIZATION 12/31/25

($ millions)Amount%
Total debt67,002105.1
Stockholders' equity(3,270)-5.1
Total capitalization63,732100.0

1,767,117,285 shares outstanding at 27 July 2026 (cover page of the 10-Q filed 3 August 2026).

LONG-TERM DEBT 12/31/25

($ millions)Amount
Long-term debt, incl. current maturities64,503
Long-term debt, noncurrent58,941
Current maturities6,056
Short-term borrowings / commercial paper2,499

CAPITAL STOCK 12/31/25

Common shares authorized4,000,000,000
Common shares issued1,838,678,628
Treasury shares70,802,593
Par or stated value per share ($)0.01
Outstanding at 7/27/261,767,117,285

DIVIDENDS DECLARED/PAID

Fiscal yearPer share $Payout %
20256.65281.8
20246.29263.2
20235.99220.2
20225.7186.1
20215.3182.3

HISTORY AND BUSINESS

HISTORY: Incorporated in Delaware.

BUSINESS: Classified by the SEC under Standard Industrial Classification 2834, Pharmaceutical Preparations. Large accelerated filer. Principal executive office: 1 North Waukegan Road, North Chicago, IL 60064. Fiscal year ends December 31. For a description of the business, see Item 1 of the latest 10-K.

CONSOLIDATED INCOME ACCOUNT, YEARS ENDED

($ millions)12/31/2512/31/2412/31/23
Revenues61,16056,33454,318
Cost of revenues18,20416,90420,415
Research and development9,09612,7917,675
Selling, general and administrative14,01014,75212,872
Depreciation and amortization762764752
Operating income15,0759,13712,757
Interest expense2,8932,8082,224
Income before income taxes6,5973,7166,250
Income taxes2,364(570)1,377
Net income4,2264,2784,863
Earned per share, diluted ($)2.362.392.72
Dividends per share ($)6.656.295.99

CONSOLIDATED BALANCE SHEET

($ millions)12/31/2512/31/24
Cash and equivalents5,2295,524
Receivables, net12,58910,919
Inventories4,9514,181
Total current assets29,06225,582
Property, plant and equipment, net5,6285,134
Goodwill35,64034,956
Total assets133,960135,161
Total current liabilities43,28938,749
Long-term debt58,94160,340
Stockholders' equity(3,270)3,325
Total liabilities and equity133,960135,161

TEN-YEAR STATISTICS: FISCAL YEARS ($ millions except per share)

Fiscal year endedRevenuesOper. incomeNet incomeNet margin %EPS diluted $Div. per share $Oper. cash flowCapital expend.Free cash flowTotal assetsTotal liabilitiesTotal debtStockholders' equityROE %Debt / equity
12/31/2561,16015,0754,2266.92.366.6519,0301,21417,816133,960137,188d67,002(3,270)-129.2-20.49
12/31/2456,3349,1374,2787.62.396.2918,80697417,832135,161131,797d66,8413,325128.720.10
12/31/2354,31812,7574,8639.02.725.9922,83977722,062134,711124,314d59,24510,36046.95.72
12/31/2258,05418,11711,83620.46.635.7124,94369524,248138,805121,518d63,12917,25468.63.66
12/31/2156,19717,92411,54220.56.455.3122,77778721,990146,529131,093d75,97615,40874.94.93
12/31/2045,80411,3634,61610.12.724.8417,58879816,790150,565137,468d84,98213,07635.36.50
12/31/1933,26612,9837,88223.75.284.3913,32455212,77289,11597,287d67,233(8,172)-96.5-8.23
12/31/1832,7536,3835,68717.43.663.9513,42763812,78959,35267,798d40,310(8,446)-67.3-4.77
12/31/1728,2169,5455,30918.83.302.639,9605299,43170,78665,689d37,3685,097104.27.33
12/31/1625,6389,3405,95323.23.632.357,0414796,56266,09961,463d36,8424,636128.47.95

Net margin = net income ÷ revenues; ROE = net income ÷ year-end stockholders’ equity; total debt = long-term debt including current maturities plus short-term borrowings/commercial paper, as tagged in XBRL; free cash flow = operating cash flow − purchases of property, plant and equipment; d = derived as total assets − total equity where the filing does not tag total liabilities; – = not reported in XBRL for that year.

REGISTRANT:

AbbVie Inc.
CIK 1551152 · EIN 32-0375147

PRINCIPAL OFFICE:

1 North Waukegan Road, North Chicago, IL 60064
Tel.: (847) 932-7900

INCORPORATED:

Delaware

INDUSTRY (SEC SIC CODE):

2834 · Pharmaceutical Preparations

FILER STATUS:

Large accelerated filer

LATEST ANNUAL REPORT:

10-K for period ended 12/31/25, filed 20 February 2026

RECENT FILINGS (ANNUAL REPORT REFERENCES BELOW):

10/5/268-Kperiod 10/5/26
9/3/268-Kperiod 9/3/26
8/18/268-Kperiod 8/18/26
8/5/268-Kperiod 8/4/26
8/3/2610-Qperiod 6/30/26
7/31/268-Kperiod 7/31/26
7/6/268-Kperiod 7/6/26
6/22/268-Kperiod 6/18/26

Sources: SEC XBRL company facts (all financial figures) · SEC submissions (registrant, address, SIC, filings) · annual reports: 10-K FY2025 (filed 2/20/26) · 10-K FY2024 (filed 2/14/25) · 10-K FY2023 (filed 2/20/24) · 10-K FY2022 (filed 2/17/23) · 10-K FY2021 (filed 2/18/22) · 10-K FY2020 (filed 2/19/21) · 10-K FY2019 (filed 2/21/20) · 10-K FY2018 (filed 2/27/19). Values are the latest figures filed for each fiscal year (restated where a later 10-K restated them). Ratios and free cash flow are Pathos calculations from those figures. Retrieved 31 October 2026.

Data from SEC filings. © 2026 Pathos Investments · pathosinvestments.com · For educational purposes only. Not investment advice.

Data from SEC filings  ·  Educational only  ·  Not investment advice